Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection | Zendy

YuTse Tsan | Zendy; ChangHsing Lee | Zendy; JungDer Wang | Zendy; PauChung Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection

Author(s) -

YuTse Tsan,

ChangHsing Lee,

JungDer Wang,

PauChung Chen

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.36.0917

Subject(s) - medicine , hepatocellular carcinoma , statin , cohort , hazard ratio , hepatitis b virus , proportional hazards model , population , cohort study , incidence (geometry) , gastroenterology , immunology , confidence interval , virus , environmental health , physics , optics

Statins have potential protective effects against cancers, but no studies have focused on patients with chronic hepatitis B virus (HBV) infection. The purpose of this study was to investigate the association between the use of statins in HBV-infected patients and the risk of hepatocellular carcinoma (HCC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research